News Focus
News Focus
icon url

poorgradstudent

03/14/13 11:59 AM

#158304 RE: dav1234 #158299

Gern:

I only had a speculative position and sold half of that today for a 15% loss. I'll keep a few shares around as part of my collection of lottery tickets (right beside my leftover PYMX). It was always a speculation based on phase I results, and I don't think the CC clouded the data to date. Rather, it just seems that there will be better opportunities to buy more in the future, if or when the time comes.

I get why the company is not jumping into trials ahead of accruing some more data. But the spend rate in the meantime is bothersome. The CC was amusing, and I guess it's nice to hear a caller call out management. But really you can pose those questions regarding compensation versus achievement to 90% of biotech CEOs. That, in and of itself, didn't drive my decision.
icon url

iwfal

03/14/13 12:00 PM

#158305 RE: dav1234 #158299

GERN -

However, concerns over an ongoing investigation into lab value abnormalities from its essential thrombocythemia study, plus opaque visibility on imetelstat progress have prompted a number of firms to cut their ratings.



The opacity has, of course, been my primary concern over GERN. As usual opacity is an indicator of future problems. (Right now there is only one biotech I would trust if they were opaque on a significant subject. Trust is something hard earned and easily squandered.)
icon url

jessellivermore

03/14/13 12:17 PM

#158310 RE: dav1234 #158299

OT Geron ":>)

Biotech Values..get it.

Geron has to be the longest running "Game Show" on the biotech channel. Dr. O'Karma, acting wizard, will be currently conjuring up...what...Telomeres, magical cancer cures, stem cells...repair of your chord injury..step right up..er..ops.

GERN has long proven that fantastic science and miraculous cure claims are right there with the halcyon days of the patent medicines, when patent medicines provided the lions share of ad revenues to commercial journals, and medicine cons were the King of Cons..

I have not followed GERN lately, but for most of O'Karma's tenure, most of the revenue generation was accomplished by issuing some wild fantastic piece of information related to GERN's progress or discovery in some important aspect of medicine. The PPS would rise as Gern's new age defying technology was trotted out...Shortly would come the new offering...The Amazing..Dr. Okarma...he has mastered making money disappear...only to see it appeare in his own pocket...

":>) JL